The Duchenne muscular dystrophy market is witnessing steady growth driven by advancements in gene therapies, exon-skipping drugs, and corticosteroid alternatives. Increasing diagnosis rates ...

Echocardiography may be at the vanguard for early and rapid detection of heart issues indicative of Duchenne muscular ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

Discover the challenges and opportunities for Keros Therapeutics, Inc., including FDA designations, partnerships, and ...

Global Duchenne Muscular Dystrophy Drugs Market Report 2023: Sector is Expected to Reach $4 Billion by 2028 at a CAGR of 11.88% - ResearchAndMarkets.com May 18, 2023 07:21 AM Eastern Daylight Time ...

For adults with Duchenne muscular dystrophy, swallowing-related impairments are associated with age, inspiratory muscle strength, and autonomic dysfunction, say the results of a new study. CMR ...

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients. Delandistrogene moxeparvovec ...

The city of Rockford dedicated a memorial plaque to one of their own, who died in November to a form of muscular dystrophy.

Managing osteoporosis and bone health in Duchenne muscular dystrophy occurs in a high-risk environment for fractures due to disease-related loss of muscle and movement, adverse effects of ...

Cardiomyopathy is the leading cause of death in patients with Duchenne muscular dystrophy, with roughly 90% developing a dilated cardiomyopathy by age 18. 2,3 Cardiomyocyte degeneration results in ...

Duchenne muscular dystrophy has a prevalence of 1 in 35,000 males. [12] The symptoms of Duchenne muscular dystrophy initially include delayed motor milestones and weakness of the proximal muscles ...